MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS

MICRO-RNAs OF NEUTROPHILS IN RENAL ANCA-ASSOCIATED VASCULITIS

Activation of neutrophils by ANCA ("Anti-Neutrophil Cytoplasm Antibodies") and subsequent microvascular endothelial cell damage is the main feature of ANCA-associated vasculitis (AAV), a severe autoimmune disease that often targets the kidney. There is no specific treatment for AAV to date and 25% of patients with renal damage evolve towards end-stage renal disease, requiring dialysis and kidney transplantation. In addition, there is no reliable biological marker of the disease activity available, which makes the diagnostic, follow-up and treatment of patients difficult. Therefore, the identification of new therapeutic targets and non-invasive biomarkers constitutes a major clinical challenge to improve AAV patients care and to ameliorate their renal outcome.

Inclusion Criteria for patients:

• Adult patients aged over 18 years
• Patients with Granulomatosis with polyangiitis or microscopic polyangiitis meeting the criteria of Chapel Hill.
• corticosteroid treatment <20 mg / day.
• Informed consent: oral for participation in research and writing for biological collection.

Inclusion Criteria for controls patients:

- healthy-topics matched for age, recruited from the Etablissement français du sang or in the Department of Internal Medicine of Nantes University Hospital

Non Inclusion Criteria:

• ANCA-associated vasculitis with Eosinophilic granulomatosis with polyangiitis (AAV-EGPA).
• Infectious or progressive tumor pathology.
• Pregnancy, lactation
• Treatment with cyclophosphamide in the 6 months prior to inclusion.
• Terminal chronic renal failure, presence of organ allograft.
• Thrust Patients receiving corticosteroids> 20 mg / d in the previous 4 weeks.
• Inability to give informed about information (subject in emergencies, understanding of the subject of difficulty, ...)
• Minor subject, under judicial protection, guardianship